Emergent BioSolutions (NYSE:EBS) Upgraded to Buy at StockNews.com

Emergent BioSolutions (NYSE:EBS) was upgraded by research analysts at StockNews.com from a “hold” rating to a “buy” rating in a research note issued to investors on Tuesday.

EBS has been the subject of a number of other research reports. Benchmark raised their price objective on Emergent BioSolutions from $8.00 to $12.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. HC Wainwright reissued a “buy” rating and issued a $15.00 price target on shares of Emergent BioSolutions in a report on Friday, January 10th.

Emergent BioSolutions Trading Up 1.1 %

Shares of EBS stock opened at $9.46 on Tuesday. The company has a current ratio of 2.88, a quick ratio of 1.47 and a debt-to-equity ratio of 1.30. Emergent BioSolutions has a 1 year low of $1.42 and a 1 year high of $15.10. The firm’s fifty day simple moving average is $9.37 and its 200 day simple moving average is $9.18. The firm has a market capitalization of $512.58 million, a P/E ratio of -2.31 and a beta of 1.60.

Institutional Trading of Emergent BioSolutions

A number of hedge funds and other institutional investors have recently made changes to their positions in EBS. State Street Corp boosted its position in Emergent BioSolutions by 864.7% in the 3rd quarter. State Street Corp now owns 1,911,327 shares of the biopharmaceutical company’s stock valued at $15,960,000 after buying an additional 1,713,200 shares during the last quarter. Oak Hill Advisors LP acquired a new position in Emergent BioSolutions in the 3rd quarter worth $9,296,000. American Century Companies Inc. grew its holdings in shares of Emergent BioSolutions by 240.9% during the second quarter. American Century Companies Inc. now owns 881,893 shares of the biopharmaceutical company’s stock worth $6,015,000 after buying an additional 623,201 shares in the last quarter. Assenagon Asset Management S.A. raised its holdings in shares of Emergent BioSolutions by 74.5% in the third quarter. Assenagon Asset Management S.A. now owns 741,552 shares of the biopharmaceutical company’s stock valued at $6,192,000 after purchasing an additional 316,700 shares during the last quarter. Finally, Federated Hermes Inc. lifted its position in Emergent BioSolutions by 1,314.0% during the 2nd quarter. Federated Hermes Inc. now owns 273,287 shares of the biopharmaceutical company’s stock worth $1,864,000 after buying an additional 253,960 shares in the last quarter. 78.40% of the stock is currently owned by institutional investors and hedge funds.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.